Cargando…

CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma

BACKGROUND: Histone deacetylase inhibitors (HDACIs) have distinctive epigenetic targets involved in hepatocarcinogenesis and chemoresistance. A recent phase I/II study reported the possibility of HDACI as a chemosensitizer in sorafenib-resistant patients. In this study, we evaluated whether CKD-5, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Young, Lee, Yun Bin, Cho, Eun Ju, Lee, Jeong-Hoon, Yu, Su Jong, Kim, Yoon Jun, Yoon, Jung-Hwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559883/ https://www.ncbi.nlm.nih.gov/pubmed/33059615 http://dx.doi.org/10.1186/s12885-020-07471-3

Ejemplares similares

Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK
por: Lee, Seulki, et al.
Publicado: (2018)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma
por: Choi, Seung Ah, et al.
Publicado: (2016)

Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
por: Kim, Hwi Young, et al.
Publicado: (2018)

Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma
por: Streubel, Gundula, et al.
Publicado: (2021)

Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib
por: Yoo, Jeong-Ju, et al.
Publicado: (2018)

In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells
por: Liu, Tsang-Pai, et al.
Publicado: (2017)

Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria
por: Cho, Yuri, et al.
Publicado: (2017)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
por: Freese, Kim, et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor, in a Zebrafish Model of Neuromuscular Junction Disorders
por: Jeong, Hui Su, et al.
Publicado: (2022)

Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma
por: Mayer, Mascha, et al.
Publicado: (2022)

Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis
por: Park, Jin Kyun, et al.
Publicado: (2020)

Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells
por: Moon, Byul, et al.
Publicado: (2022)

Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
por: Choi, Na Ryung, et al.
Publicado: (2022)

The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma
por: Wang, Mingda, et al.
Publicado: (2019)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model
por: Pająk, Beata, et al.
Publicado: (2021)

Synergistic association of resveratrol and histone deacetylase inhibitors as treatment in amyotrophic lateral sclerosis
por: Parrella, Edoardo, et al.
Publicado: (2022)

Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro
por: Oh, Bo Ram, et al.
Publicado: (2017)

Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation
por: Son, Cheol-Hun, et al.
Publicado: (2014)

Histone Deacetylase 6 Inhibitor CKD-WID Suppressed Monosodium Urate-Induced Osteoclast Formation by Blocking Calcineurin-NFAT Pathway in RAW 264.7 Cells
por: Kim, Seong-Kyu, et al.
Publicado: (2023)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo
por: Liu, Shilei, et al.
Publicado: (2019)

Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
por: Liu, Jianhua, et al.
Publicado: (2017)

Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1
por: Martínez-Bonet, Marta, et al.
Publicado: (2015)

Synergistic Interaction of Histone Deacetylase 6- and MEK-Inhibitors in Castration-Resistant Prostate Cancer Cells
por: Corno, Cristina, et al.
Publicado: (2020)

Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors
por: Lee, Su-Chan, et al.
Publicado: (2016)

Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
por: Garmpis, Nikolaos, et al.
Publicado: (2021)

Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer
por: Paller, Channing J, et al.
Publicado: (2014)

Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy
por: Ruttala, Hima Bindu, et al.
Publicado: (2017)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oucuup8sta5d776ro9t51f2gq2